Spectral CT scans and blood markers to track heart recovery after a heart attack
Tests spectral CT and blood markers in adults after a serious heart attack.
Plain-language title generated from the registry record
Registry title: Using Advanced CT Scans and Blood Markers to Better Understand Heart Damage and Recovery After a Heart Attack
Key facts
- Where
- Madrid, Salamanca, and Valencia, SpainSee the 4 sites
Where in Spain
- Hospital La PrincesaMadrid, SpainTaking people
- Hospital Ramón y CajalMadrid, SpainTaking people
- Complejo Asistencial Universitario de SalamancaSalamanca, SpainTaking people
- Hospital Clinico Universitario de ValenciaValencia, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Instituto de Investigación Biomédica de Salamanca
- Trial code
- NCT07268391
- Record updated
- 11 August 2026
- Original description
Acute myocardial infarction with ST-segment elevation (STEMI) remains a leading cause of morbidity and mortality worldwide. Although advances in reperfusion therapy have reduced early mortality, many patients later develop adverse ventricular remodeling (AVR), which increases the risk of heart failure and cardiovascular death. Current imaging methods, such as echocardiography and cardiac magnetic resonance (CMR), provide valuable prognostic information but have limitations in availability, cost, and their ability to predict AVR early and individually.Read full original descriptionShow less
SPEctral CT and miRna In Acute Myocardial Infarction for Comprehensive Adverse Remodeling Evaluation
Acute myocardial infarction with ST-segment elevation (STEMI) remains a leading cause of morbidity and mortality worldwide. Although advances in reperfusion therapy have reduced early mortality, many patients later develop adverse ventricular remodeling (AVR), which increases the risk of heart failure and cardiovascular death. Current imaging methods, such as echocardiography and cardiac magnetic resonance (CMR), provide valuable prognostic information but have limitations in availability, cost, and their ability to predict AVR early and individually.
Spectral computed tomography (CT) is an emerging imaging technique that can characterize myocardial tissue, quantify infarct size, assess microvascular obstruction, and detect complications, with lower contrast and radiation requirements compared to conventional CT. In parallel, circulating microRNAs (miRNAs) have been identified as stable and non-invasive biomarkers that reflect key biological processes in post-infarction remodeling. Several miRNAs are linked to fibrosis, apoptosis, and ventricular remodeling, suggesting their potential to complement imaging findings in risk prediction.
This study proposes a multicenter, prospective cohort of patients with STEMI and reduced left ventricular function to evaluate whether combining spectral CT tissue characterization with serum miRNA profiling can improve early prediction of AVR. The main objective is to generate and validate a multiparametric prognostic model integrating imaging and molecular biomarkers to identify high-risk patients who may benefit from closer monitoring and tailored therapeutic strategies.
Inclusion: Adults ≥18 years; First STEMI treated with primary PCI; Left ventricular ejection fraction (LVEF) ≤45% during index hospitalization; Ability to provide informed consent.
Exclusion: Prior myocardial infarction or known cardiomyopathy; Life expectancy <1 year due to non-cardiac conditions; Chronic kidney disease with eGFR <30 mL/min/1.73 m²; Contraindication to iodinated contrast media; Contraindication to CT or MRI imaging.